Segments of Business and Geographic Areas (Tables)

12 Months Ended

Jan. 02, 2022

Jan. 03, 2021

Segment Reporting [Abstract]

Schedule of Sales by Segment of Business

	Sales to Customers				% Change
(Dollars in Millions)	2021		2020	2019	’21 vs. ’20		’20 vs. ’19
Consumer Health
OTC
U.S.	$	2,594	2,460	2,010	5.4	%	22.4
International	2,634		2,364	2,434	11.4		(2.9)
Worldwide	5,227		4,824	4,444	8.4		8.5
Skin Health/Beauty
U.S.	2,400		2,350	2,392	2.1		(1.7)
International	2,141		2,100	2,201	1.9		(4.6)
Worldwide	4,541		4,450	4,593	2.0		(3.1)
Oral Care
U.S.	637		683	621	(6.7)		9.9
International	1,008		958	906	5.1		5.7
Worldwide	1,645		1,641	1,528	0.2		7.4
Baby Care
U.S.	378		376	362	0.5		3.7
International	1,188		1,141	1,313	4.1		(13.1)
Worldwide	1,566		1,517	1,675	3.2		(9.4)
Women's Health
U.S.	13		13	12	(1.6)		8.2
International	905		888	974	1.8		(8.8)
Worldwide	917		901	986	1.8		(8.6)
Wound Care/Other
U.S.	495		480	441	3.1		8.9
International	243		240	230	1.7		4.1
Worldwide	739		720	671	2.6		7.2
TOTAL CONSUMER HEALTH
U.S.	6,516		6,362	5,839	2.4		9.0
International	8,119		7,691	8,059	5.6		(4.6)
Worldwide	14,635		14,053	13,898	4.1		1.1

PHARMACEUTICAL
Immunology
U.S.	10,843	10,175	9,641	6.6	5.5
International	5,907	4,880	4,309	21.0	13.2
Worldwide	16,750	15,055	13,950	11.3	7.9
REMICADE®
U.S.	2,019	2,508	3,079	(19.5)	(18.5)
U.S. Exports	236	346	294	(31.9)	18.0
International	935	893	1,007	4.8	(11.4)
Worldwide	3,190	3,747	4,380	(14.9)	(14.4)
SIMPONI / SIMPONI ARIA®
U.S.	1,127	1,155	1,159	(2.4)	(0.3)
International	1,148	1,088	1,029	5.5	5.8
Worldwide	2,276	2,243	2,188	1.4	2.6
STELARA®
U.S.	5,938	5,240	4,346	13.3	20.6
International	3,196	2,467	2,015	29.6	22.4
Worldwide	9,134	7,707	6,361	18.5	21.1
TREMFYA®
U.S.	1,503	926	764	62.3	21.3
International	624	421	248	48.2	69.9
Worldwide	2,127	1,347	1,012	57.9	33.2
OTHER IMMUNOLOGY
U.S.	21	—	—	**	—
International	3	11	10	(73.3)	6.4
Worldwide	24	11	10	**	6.4
Infectious Diseases
U.S.	2,249	1,735	1,597	29.7	8.6
International	3,612	1,839	1,815	96.3	1.3
Worldwide	5,861	3,574	3,413	64.0	4.7
COVID-19 VACCINE
U.S.	634	—	—	**	**
International	1,751	—	—	**	**
Worldwide	2,385	—	—	**	**
EDURANT® / rilpivirine
U.S.	41	44	50	(7.6)	(11.2)
International	953	920	812	3.6	13.3
Worldwide	994	964	861	3.1	11.9
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
U.S.	1,508	1,587	1,422	(4.9)	11.6
International	575	597	689	(3.6)	(13.4)
Worldwide	2,083	2,184	2,110	(4.6)	3.5
OTHER INFECTIOUS DISEASES
U.S.	66	104	126	(36.0)	(17.6)
International	333	323	315	3.0	2.6
Worldwide	399	427	441	(6.5)	(3.2)

Neuroscience
U.S.	3,347	3,091	2,919	8.3	5.9
International	3,664	3,457	3,409	6.0	1.4
Worldwide	7,011	6,548	6,328	7.1	3.5
CONCERTA® / methylphenidate
U.S.	172	183	233	(5.8)	(21.4)
International	495	439	463	12.8	(5.1)
Worldwide	667	622	696	7.3	(10.6)
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
U.S.	2,550	2,314	2,107	10.2	9.8
International	1,472	1,339	1,224	10.0	9.4
Worldwide	4,022	3,653	3,330	10.1	9.7
RISPERDAL CONSTA®
U.S.	287	296	314	(2.9)	(5.9)
International	305	346	374	(11.8)	(7.5)
Worldwide	592	642	688	(7.7)	(6.8)
OTHER NEUROSCIENCE
U.S.	338	298	266	13.3	12.4
International	1,391	1,334	1,349	4.3	(1.1)
Worldwide	1,729	1,632	1,614	6.0	1.1
Oncology
U.S.	5,958	5,092	4,299	17.0	18.5
International	8,590	7,275	6,393	18.1	13.8
Worldwide	14,548	12,367	10,692	17.6	15.7
DARZALEX®
U.S.	3,169	2,232	1,567	42.0	42.4
International	2,854	1,958	1,430	45.8	36.9
Worldwide	6,023	4,190	2,998	43.8	39.8
ERLEADA®
U.S.	813	583	297	39.3	96.1
International	478	176	35	* *	* *
Worldwide	1,291	760	332	70.0	* *
IMBRUVICA®
U.S.	1,747	1,821	1,555	(4.0)	17.1
International	2,622	2,307	1,856	13.6	24.3
Worldwide	4,369	4,128	3,411	5.8	21.0
ZYTIGA® /abiraterone acetate
U.S.	119	373	810	(68.1)	(54.0)
International	2,178	2,097	1,985	3.9	5.6
Worldwide	2,297	2,470	2,795	(7.0)	(11.6)
OTHER ONCOLOGY
U.S.	110	83	70	31.7	18.6
International	458	738	1,087	(37.9)	(32.1)
Worldwide	568	821	1,158	(30.8)	(29.1)

Pulmonary Hypertension
U.S.	2,365	2,133	1,684	10.9	26.6
International	1,085	1,015	939	6.9	8.2
Worldwide	3,450	3,148	2,623	9.6	20.0
OPSUMIT®
U.S.	1,147	1,008	766	13.7	31.7
International	672	631	562	6.6	12.3
Worldwide	1,819	1,639	1,327	11.0	23.5
UPTRAVI®
U.S.	1,056	955	714	10.5	33.8
International	181	138	105	31.1	30.9
Worldwide	1,237	1,093	819	13.1	33.5
OTHER
U.S.	163	169	205	(3.7)	(17.6)
International	232	247	272	(5.9)	(9.2)
Worldwide	395	416	476	(5.0)	(12.8)
Cardiovascular / Metabolism / Other
U.S.	3,192	3,509	3,734	(9.0)	(6.0)
International	1,268	1,369	1,458	(7.4)	(6.1)
Worldwide	4,460	4,878	5,192	(8.6)	(6.0)
XARELTO®
U.S.	2,438	2,345	2,313	4.0	1.4
International	—	—	—	—	—
Worldwide	2,438	2,345	2,313	4.0	1.4
INVOKANA® / INVOKAMET®
U.S.	308	564	536	(45.4)	5.2
International	254	231	199	9.9	16.3
Worldwide	563	795	735	(29.3)	8.2
PROCRIT® / EPREX®
U.S.	223	277	505	(19.7)	(45.1)
International	256	274	285	(6.8)	(3.8)
Worldwide	479	552	790	(13.3)	(30.2)
OTHER
U.S.	223	323	380	(31.0)	(15.1)
International	758	864	974	(12.2)	(11.3)
Worldwide	981	1,186	1,353	(17.3)	(12.4)
TOTAL PHARMACEUTICAL
U.S.	27,954	25,735	23,874	8.6	7.8
International	24,126	19,837	18,324	21.6	8.3
Worldwide	52,080	45,572	42,198	14.3	8.0

MEDICAL DEVICES
Interventional Solutions
U.S.	1,836	1,452	1,443	26.4	0.6
International	2,135	1,594	1,554	34.0	2.6
Worldwide	3,971	3,046	2,997	30.4	1.6
Orthopaedics
U.S.	5,126	4,779	5,319	7.3	(10.2)
International	3,462	2,984	3,520	16.0	(15.2)
Worldwide	8,588	7,763	8,839	10.6	(12.2)
HIPS
U.S.	883	793	863	11.4	(8.2)
International	602	487	575	23.6	(15.3)
Worldwide	1,485	1,280	1,438	16.0	(11.0)
KNEES
U.S.	787	743	889	5.9	(16.4)
International	538	427	591	26.1	(27.8)
Worldwide	1,325	1,170	1,480	13.3	(21.0)
TRAUMA
U.S.	1,819	1,648	1,652	10.4	(0.2)
International	1,066	966	1,068	10.4	(9.6)
Worldwide	2,885	2,614	2,720	10.4	(3.9)
SPINE, SPORTS & OTHER
U.S.	1,637	1,595	1,915	2.6	(16.7)
International	1,256	1,104	1,286	13.8	(14.1)
Worldwide	2,893	2,699	3,201	7.2	(15.7)
Surgery
U.S.	3,867	3,249	3,828	19.0	(15.1)
International	5,945	4,983	5,673	19.3	(12.2)
Worldwide	9,812	8,232	9,501	19.2	(13.4)
ADVANCED
U.S.	1,761	1,535	1,637	14.9	(6.2)
International	2,861	2,304	2,458	24.1	(6.2)
Worldwide	4,622	3,839	4,095	20.4	(6.2)
GENERAL
U.S.	2,105	1,714	2,192	22.7	(21.8)
International	3,085	2,679	3,215	15.2	(16.7)
Worldwide	5,190	4,392	5,406	18.1	(18.8)
Vision
U.S.	1,857	1,557	1,794	19.3	(13.2)
International	2,831	2,362	2,830	19.8	(16.5)
Worldwide	4,688	3,919	4,624	19.6	(15.2)
CONTACT LENSES / OTHER
U.S.	1,398	1,213	1,304	15.2	(7.0)
International	2,043	1,781	2,088	14.7	(14.7)
Worldwide	3,440	2,994	3,392	14.9	(11.7)

SURGICAL
U.S.	459		344	490	33.5		(29.7)
International	788		581	742	35.7		(21.7)
Worldwide	1,248		925	1,232	34.9		(24.9)
TOTAL MEDICAL DEVICES
U.S.	12,686		11,036	12,384	14.9		(10.9)
International	14,374		11,923	13,579	20.6		(12.2)
Worldwide	27,060		22,959	25,963	17.9		(11.6)
WORLDWIDE
U.S.	47,156		43,133	42,097	9.3		2.5
International	46,619		39,451	39,962	18.2		(1.3)
Worldwide	$	93,775	82,584	82,059	13.6	%	0.6

*Certain prior year amounts have been reclassified to conform to current year presentation

**Percentage greater than 100% or not meaningful

Schedule of Segment Reporting Information

	Income (Loss) Before Tax				Identifiable Assets
(Dollars in Millions)	2021 (3)		2020 (4)	2019 (5)	2021		2020
Consumer Health	$	1,294	(1,064)	2,061	$	25,081	27,355
Pharmaceutical	18,181		15,462	8,816	64,376		66,158
Medical Devices	4,373		3,044	7,286	53,372		49,578
Total	23,848		17,442	18,163	142,829		143,091
Less: Expense not allocated to segments (1)	1,072		945	835
General corporate (2)					39,189		31,803
Worldwide total	$	22,776	16,497	17,328	$	182,018	174,894

	Additions to Property, Plant & Equipment				Depreciation and Amortization
(Dollars in Millions)	2021		2020	2019	2021		2020	2019
Consumer Health	$	331	248	328	$	759	785	765
Pharmaceutical	1,198		863	950	4,029		4,006	3,910
Medical Devices	1,933		1,980	1,912	2,286		2,140	2,014
Segments total	3,462		3,091	3,190	7,074		6,931	6,689
General corporate	190		256	308	316		300	320
Worldwide total	$	3,652	3,347	3,498	$	7,390	7,231	7,009

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

	Sales to Customers				Long-Lived Assets (6)
(Dollars in Millions)	2021		2020	2019	2021		2020
United States	$	47,156	43,133	42,097	$	48,586	49,951
Europe	23,594		18,980	18,466	43,257		49,363
Western Hemisphere excluding U.S.	5,750		5,335	5,941	2,708		2,734
Asia-Pacific, Africa	17,275		15,136	15,555	5,035		5,484
Segments total	93,775		82,584	82,059	99,586		107,532
General corporate					1,014		1,029
Other non long-lived assets					81,418		66,333
Worldwide total	$	93,775	82,584	82,059	$	182,018	174,894

See Note 1 for a description of the segments in which the Company operates.

Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues.

(1)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.

(2)General corporate includes cash, cash equivalents and marketable securities.

(3)Consumer Health includes:

•Litigation expense of $1.6 billion, primarily talc related reserves

•A restructuring related charge of $0.1 billion

Pharmaceutical includes:

•Litigation expense of $0.6 billion, primarily related to Risperdal

•Divestiture gains of $0.6 billion

•Gains on securities of $0.5 billion

•A restructuring related charge of $0.1 billion

Medical Devices includes:

•A restructuring related charge of $0.3 billion

•An in-process research and development expense of $0.9 billion

•A Medical Device Regulation charge of $0.2 billion

•Litigation expense of $0.1 billion

(4)    Consumer Health includes:

•Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements.

Pharmaceutical includes:

•Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation

•An unrealized gain on securities of $0.5 billion

•A restructuring related charge of $0.1 billion

Medical Devices includes:

•A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.

•Litigation expense of $0.3 billion

•A restructuring related charge of $0.3 billion

•An in-process research and development expense of $0.2 billion

•A Medical Device Regulation charge of $0.1 billion

(5)     Consumer Health includes:

•A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO

•Litigation expense of $0.4 billion

•A restructuring related charge of $0.1 billion

Pharmaceutical includes:

•Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation

•An in-process research and development expense of $0.9 billion related to the Alios asset

•A research and development expense of $0.3 billion for an upfront payment related to argenx

•An unrealized gain on securities of $0.6 billion

•Actelion acquisition and integration related costs of $0.2 billion

•A restructuring charge of $0.1 billion

Medical Devices includes:

•A gain of $2.0 billion from the divestiture of the ASP business

•A restructuring related charge of $0.4 billion

•Litigation expense of $0.4 billion

•Auris Health acquisition and integration related costs of $0.1 billion

(6) Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.